122 related articles for article (PubMed ID: 29944950)
1. Expression and clinical significance of COMPASS family of histone methyltransferases in clear cell renal cell carcinoma.
Kumar A; Kumari N; Rai A; Singh SK; Kakkar N; Prasad R
Gene; 2018 Oct; 674():31-36. PubMed ID: 29944950
[TBL] [Abstract][Full Text] [Related]
2. Expression profile of H3K4 demethylases with their clinical and pathological correlation in patients with clear cell renal cell carcinoma.
Kumar A; Kumari N; Nallabelli N; Sharma U; Rai A; Singh SK; Kakkar N; Prasad R
Gene; 2020 May; 739():144498. PubMed ID: 32097694
[TBL] [Abstract][Full Text] [Related]
3. SETDB2 and RIOX2 are differentially expressed among renal cell tumor subtypes, associating with prognosis and metastization.
Ferreira MJ; Pires-Luís AS; Vieira-Coimbra M; Costa-Pinheiro P; Antunes L; Dias PC; Lobo F; Oliveira J; Gonçalves CS; Costa BM; Henrique R; Jerónimo C
Epigenetics; 2017; 12(12):1057-1064. PubMed ID: 29099276
[TBL] [Abstract][Full Text] [Related]
4.
Su X; Zhang J; Mouawad R; Compérat E; Rouprêt M; Allanic F; Parra J; Bitker MO; Thompson EJ; Gowrishankar B; Houldsworth J; Weinstein JN; Tost J; Broom BM; Khayat D; Spano JP; Tannir NM; Malouf GG
Cancer Res; 2017 Sep; 77(18):4835-4845. PubMed ID: 28754676
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional regulation by the KMT2 histone H3K4 methyltransferases.
Park K; Kim JA; Kim J
Biochim Biophys Acta Gene Regul Mech; 2020 Jul; 1863(7):194545. PubMed ID: 32194213
[TBL] [Abstract][Full Text] [Related]
6. Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication.
Pires-Luís AS; Vieira-Coimbra M; Vieira FQ; Costa-Pinheiro P; Silva-Santos R; Dias PC; Antunes L; Lobo F; Oliveira J; Gonçalves CS; Costa BM; Henrique R; Jerónimo C
Epigenetics; 2015; 10(11):1033-43. PubMed ID: 26488939
[TBL] [Abstract][Full Text] [Related]
7. Reduction in H3K4me patterns due to aberrant expression of methyltransferases and demethylases in renal cell carcinoma: prognostic and therapeutic implications.
Kumar A; Kumari N; Sharma U; Ram S; Singh SK; Kakkar N; Kaushal K; Prasad R
Sci Rep; 2019 Jun; 9(1):8189. PubMed ID: 31160694
[TBL] [Abstract][Full Text] [Related]
8. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC).
Evelönn EA; Degerman S; Köhn L; Landfors M; Ljungberg B; Roos G
Tumour Biol; 2016 Aug; 37(8):10219-28. PubMed ID: 26831665
[TBL] [Abstract][Full Text] [Related]
10. Aberrant Activity of Histone-Lysine N-Methyltransferase 2 (KMT2) Complexes in Oncogenesis.
Poreba E; Lesniewicz K; Durzynska J
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33302406
[TBL] [Abstract][Full Text] [Related]
11. Histone-lysine N-methyltransferase 2 (KMT2) complexes - a new perspective.
Poreba E; Lesniewicz K; Durzynska J
Mutat Res Rev Mutat Res; 2022; 790():108443. PubMed ID: 36154872
[TBL] [Abstract][Full Text] [Related]
12. The role of histone methylation in renal cell cancer: an update.
Hou Y; Yuan Y; Li Y; Wang L; Hu J; Liu X
Mol Biol Rep; 2023 Mar; 50(3):2735-2742. PubMed ID: 36575323
[TBL] [Abstract][Full Text] [Related]
13. The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis.
Shilatifard A
Annu Rev Biochem; 2012; 81():65-95. PubMed ID: 22663077
[TBL] [Abstract][Full Text] [Related]
14. SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12.
González-Rodríguez P; Engskog-Vlachos P; Zhang H; Murgoci AN; Zerdes I; Joseph B
Cell Death Dis; 2020 Jan; 11(1):69. PubMed ID: 31988284
[TBL] [Abstract][Full Text] [Related]
15. Biochemical perspectives on targeting KMT2 methyltransferases in cancer.
Zhai X; Brownell JE
Trends Pharmacol Sci; 2021 Aug; 42(8):688-699. PubMed ID: 34074527
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of SET domain-containing proteins and decreased expression of Rad51 in different classes of renal cell carcinoma.
Liu S; Li Y; Xu H; Wang K; Li N; Li J; Sun T; Xu Y
Biosci Rep; 2016 Jul; 36(3):. PubMed ID: 27170370
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of two lipid metabolism enzymes, HADHA and ACAT2, in clear cell renal cell carcinoma.
Zhao Z; Lu J; Han L; Wang X; Man Q; Liu S
Tumour Biol; 2016 Jun; 37(6):8121-30. PubMed ID: 26715271
[TBL] [Abstract][Full Text] [Related]
19. KMT2 Family of H3K4 Methyltransferases: Enzymatic Activity-dependent and -independent Functions.
Van HT; Xie G; Dong P; Liu Z; Ge K
J Mol Biol; 2024 Apr; 436(7):168453. PubMed ID: 38266981
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases.
Heinzelmann J; Unrein A; Wickmann U; Baumgart S; Stapf M; Szendroi A; Grimm MO; Gajda MR; Wunderlich H; Junker K
Ann Surg Oncol; 2014 Mar; 21(3):1046-54. PubMed ID: 24242678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
